Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical StudyMichèle Cavo, Michele Baccarani, Sonia Ronconi et al.|Journal of Clinical Oncology|2007Cited by 374
Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.Elena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2007Cited by 3
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.Elena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2009Cited by 1
Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone.Elena Zamagni, Michèle Cavo, Lelia Valdrè et al.|Blood|2007Cited by 1